Navigation Links
Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
Date:10/18/2011

t timelines, future IND filings for new product candidates, and regulatory filings and submissions for any of our product candidates in clinical development; fluctuations in our operating results, in particular if EYLEATM or any of our other late-stage product candidates is approved for marketing, and our revenues, market share, and/or market acceptance of EYLEATM or such other products do not meet the expectations of investors or analysts; the possible success of any of our current or future product candidates; the determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our product and drug candidates; pricing or reimbursement actions or decisions by government authorities or insurers affecting the coverage or reimbursement of any of our product candidates or competitive products; our ability to raise additional capital as needed on favorable terms; public concern as to the safety or effectiveness of any of our product candidates; the uncertainty of market acceptance of our product and drug candidates; our ability to advance new antibody product candidates into clinical development; our ability to build a successful, integrated biopharmaceutical company; competing drugs that may be superior to our product and drug candidates; the data that will be generated by ongoing and planned clinical trials and the ability to use that data to support regulatory filings, including potential applications for marketing approval for any of our product candidates; the maintenance of any of our license or collaborative relationships, including, without limitation, those with Sanofi and Bayer HealthCare; our liquidity and our expectations regarding our future cash needs and our expectations regarding the possibility of raising additional capital; the risks associated with third party intellectual property and pending or future litigation relating thereto; and completion of this offering a
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... N.C. , May 22, 2015  Research ... hosting its sixth Medical Affairs Roundtable ... (EDT) via a virtual roundtable to discuss "Medical ... Best Practices, Medical Affairs Consortium provides ... insights about the key challenges they face. The ...
(Date:5/22/2015)... The Taskforce representing Canada,s living victims ... that the Minister and Health Canada have put into this ... needs of the thalidomide survivors, and more than 70% of ... with annual adjustments for inflation. Certain of the ... based on the severity of their disability, tax free, with ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... Corporation ( www.fluidnet.net ), an innovator of advanced intravenous ... Directors has unanimously appointed Benjamin E. Bulkley as President ... company,s Founder, Jeffrey Carlisle, who will serve as Fluidnet,s ... Board of Directors, Chuck Hadley, Chairman, said, "Fluidnet is ...
... Bulletin Board: IAGX ) announced today that based on ... of August that it expects its net sales for its second ... $2.8 to $3.2 million, an increase of 158% to 195% compared ... compared to the second quarter of the previous fiscal year. ...
Cached Medicine Technology:Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer 2Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011 2Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011 3
(Date:5/25/2015)... 2015 After the sensational buzz surrounding ... human wellness company Trivedi Master Wellness™ agrees ... world-class series titled, “Consciousness is Power.” Presently, the Live-Streaming ... 2015 at the routinely allotted time from 10:00pm PST/1:00pm ... be made available to the public and accessible on ...
(Date:5/24/2015)... The Rolling Stones Zip Code summer stadium ... Petco Park. This iconic group is ready for their ... had a warmup show in Los Angeles at the Henry ... this beloved band not only played their Sticky Fingers album ... "Jumping Jack Flash," "Moonlight Mile" and "All Down the ...
(Date:5/24/2015)... May 24, 2015 EnviroLeather™ by ... “InkGard™ Plus” – a classic, rugged leather grain ... allowing difficult stains, including ink, to be easily ... colors suitable for corporate, healthcare, hospitality and education ... with EnviroLeather’s goal of developing products that are ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... 2015 With the implementation of the ... it increasingly difficult to provide their employees with a ... adequate insurance for employees stand to face strict penalties. ... integral part of a business’s success or failure. In ... Online USA Doctors has created a varying level of ...
Breaking Medicine News(10 mins):Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3
... who are smokers and have a family history of brain aneurysm ... a brain aneurysm themselves. The research is published in the December ... of the American Academy of Neurology and will appear in the ... type of stroke, called subarachnoid hemorrhage, is one of the bleeding ...
... Priority in 2009SPRINGFIELD, Ill., Dec. 31 The following is ... Illinois:The economic situation is forcing more Illinois families to face ... of people are cutting back on necessities in order to ... it,s too expensive. High health care costs are leaving ...
... mcg/hr) Not Affected RARITAN, N.J., Dec. 31 PriCara(R), ... lot of 50 microgram/hour (mcg/hr) DURAGESIC(R) (fentanyl transdermal system) ... and one lot of 50 mcg/hr fentanyl patches sold ... voluntarily recalled as a precaution from wholesalers and pharmacies. ...
... XStor Medical Systems, a,privately held Silicon Valley ... advanced clinical applications and collaborative patient care.,The ... participating,hospitals, clinics, and healthcare systems to securely ... and patients. The,XStor Imaging Platform is a ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... today announced that its subsidiary, Watson Laboratories, Inc., ... and Drug Administration to market its over-the-counter Nicotine ... 2 mg and 4 mg strengths.Nicotine Polacrilex Gum, ...
... deprivation therapy that prostate cancer patients often take gives them ... within a couple of years. Now, researchers at Johns Hopkins ... cancer cells in patients who no longer respond to this ... Cancer Research , could lead to a way to ...
Cached Medicine News:Health News:Smokers with stroke in the family 6 times more likely to have stroke too 2Health News:PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2Health News:PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 3Health News:XStor Medical Systems Announces the Release of its Imaging Platform for Connectivity Between Healthcare Enterprises 2Health News:Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum 2Health News:Why prostate cancer patients fail hormone deprivation therapy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: